Erlotinib Hydrochloride

  (er-LOH-tih-nib HY-droh-KLOR-ide)

This page contains brief information about erlotinib hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s):		Tarceva
FDA Approved:		Yes

FDA Approval for Erlotinib Hydrochloride

Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

• Non-small cell lung cancer (NSCLC).
  • It is used as first-line treatment for metastatic NSCLC in patients with tumors that have epidermal growth factor receptor (EGFR) mutations.

  • It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.

• Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.

Erlotinib hydrochloride is also being studied in the treatment of other types of cancer.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Erlotinib Hydrochloride - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Find Clinical Trials for Erlotinib Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Back to Top